Logo

AstraZeneca and MSD's Koselugo (selumetinib) Receive the EU's Approval for Neurofibromatosis Type 1 and Plexiform Neurofibromas

Share this

AstraZeneca and MSD's Koselugo (selumetinib) Receive the EU's Approval for Neurofibromatosis Type 1 and Plexiform Neurofibromas

Shots:

  • The conditional approval is based on P-II SPRINT Stratum 1 trial assessing selumetinib (PO- bid) as monothx. in pediatric patients aged >3yr. with NF1-related inoperable PNs. The trial was sponsored by NCI CTEP- conducted under a research & development agreement b/w NCI & AstraZeneca with additional support from NTAP
  • The trial showed a reduction in size of tumors with ORR (66%) in children- reduction in pain- improvement in QoL. Safety & efficacy data of the study with longer follow up will be provided as one of conditional approval
  • The therapy is approved in the US & other countries for NF1 & symptomatic- inoperable PN while other regulatory submissions of the therapy are ongoing

Ref: AstraZeneca | Image: New Europe

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions